Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-06-02 @ 5:17 PM
Study NCT ID:
NCT02643667
Status:
COMPLETED
Last Update Posted:
2025-01-08
First Post:
2015-12-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Sponsor:
Washington University School of Medicine
Organization:
Study Overview
Official Title:
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: